Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus.
Ostendorf L, Burns M, Durek P, Heinz GA, Heinrich F, Garantziotis P, Enghard P, Richter U, Biesen R, Schneider U, Knebel F, Burmester G, Radbruch A, Mei HE, Mashreghi MF, Hiepe F, Alexander T.
N Engl J Med. 2020 Sep 17;383(12):1149-1155. doi: 10.1056/NEJMoa2023325.
Pediatric lupus nephritis.
Pinheiro SVB, Dias RF, Fabiano RCG, Araujo SA, Silva ACSE.
J Bras Nefrol. 2019 Apr-Jun;41(2):252-265. doi: 10.1590/2175-8239-JBN-2018-0097. Epub 2018 Nov 14.
Urinary biomarkers for active Lupus Nephritis that have survived independent validation across cohorts.
Vodehnal S, Mohan C.
Kidney Int. 2024 Dec;106(6):1135-1145. doi: 10.1016/j.kint.2024.09.007. Epub 2024 Oct 5.
Utilization of Biomarkers in Lupus Nephritis.
Caster DJ, Powell DW.
Adv Chronic Kidney Dis. 2019 Sep;26(5):351-359. doi: 10.1053/j.ackd.2019.09.001.
Biomarkers in lupus nephritis.
Misra R, Gupta R.
Int J Rheum Dis. 2015 Feb;18(2):219-32. doi: 10.1111/1756-185X.12602.
[Osteopontin in systemic lupus erythematosus].
Kitagori K, Yoshifuji H.
Nihon Rinsho Meneki Gakkai Kaishi. 2017;40(2):118-123. doi: 10.2177/jsci.40.118.
Inflammatory markers in systemic lupus erythematosus.
Aringer M.
J Autoimmun. 2020 Jun;110:102374. doi: 10.1016/j.jaut.2019.102374. Epub 2019 Dec 4.
Systemic lupus erythematosus biomarkers: the challenging quest.
Arriens C, Wren JD, Munroe ME, Mohan C.
Rheumatology (Oxford). 2017 Apr 1;56(suppl_1):i32-i45. doi: 10.1093/rheumatology/kew407.
2013 update: Hopkins lupus cohort.
Fangtham M, Petri M.
Curr Rheumatol Rep. 2013 Sep;15(9):360. doi: 10.1007/s11926-013-0360-0.
Proteomic profiling of urine: implications for lupus nephritis.
Aljaberi N, Bennett M, Brunner HI, Devarajan P.
Expert Rev Proteomics. 2019 Apr;16(4):303-313. doi: 10.1080/14789450.2019.1592681. Epub 2019 Mar 18.
